Michael Masterman-Smith plans to bring a cure for broken government in key California Congressional swing district.
Los Angeles, CA – Dr. Michael Masterman-Smith, a pioneering cancer researcher and pharmacologist, formally filed to run for Congress in California’s 25th District, which covers Northern Los Angeles County and parts of Ventura County. The District is turning into one of the most competitive contests in the 2018 election.
Dr. Masterman-Smith’s career as a cancer biologist revolutionized the way cancer is studied and helped speed up the development of improved cancer therapies. He will take this same innovative, entrepreneurial spirit to Washington to fix our country’s most vexing problems.
Dr. Masterman-Smith brings a unique perspective to government. Pharmacological problems need a pharmacologist to fix them. Less than 8% of the U.S. Congress has any background in medicine or healthcare, yet they define the nation’s healthcare policies. He is joining a small group of candidates with medical expertise running for Congress in 2018. He is intent on introducing bills that will integrate medical cannabis into our healthcare system, prevent overmedication, provide an effective plan to deal with our opioid epidemic and put our health care system on track to sustainability. Dr. Masterman-Smith will fight to protect American scientific advancement and expand STEM education and training to keep America competitive.
Regarding his decision to run, Michael says, “Working on the frontlines in the war on cancer I know the remarkable achievements we can make. However, like cancer, if we don’t take our problems head-on, they can quickly snowball into catastrophe. In Congress, I will fight for evidence-based policymaking, an effective, affordable healthcare system, a modern economy that produces high paying 21st-century jobs, a coherent national security policy, and an environmental and climate change plan that commits the U.S. to a sustainable future.”
Dr. Masterman-Smith received his Ph.D. in Molecular & Medical Pharmacology from the David Geffen School of Medicine at UCLA and completed postdoctoral training in Biomedical Engineering in the UCLA Henry Samueli School of Engineering and Applied Sciences. He is currently the CEO at CA Labs, Inc. a boutique pharmaceutical company focused on the development of phytochemicals (plant-based drugs) to address difficult to treat conditions and diseases.